FDA approval

Colin Kerr

Posted: Wednesday, May 1, 2019

Aerie Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Rocklatan™ to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

“Rocklatan is a once-daily eye drop that is a fixed-dose combination of latanoprost and netarsudil, the active ingredient in Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor specifically designed to target the trabecular meshwork. Rhopressa works by restoring outflow through the trabecular meshwork, while latanoprost increases fluid outflow through the uveoscleral pathway,” said a company spokesman.